Country Report: Singapore - Pharmaceutical Executive


Country Report: Singapore
The Little Red Dot That Did

Pharmaceutical Executive


It is precisely Singapore's ability to fill in the blanks of global demand that enables it to consistently evolve and convert conventional disadvantages—size to agility, inexperience to enterprise—in order to designate itself as a hub for you-name-it.

Swee Yeok Chu, President & CEO EDBI - Economic Development Board Investments
In order to make biomedical sciences the fourth pillar of the economy (after electronics, engineering and chemicals), Singapore needed to solve two problems: Make the island a prime location for manufacturing in order to lure more multinationals (MNCs) and build infrastructure to enhance R&D capabilities. That meant increasing hospitals' and universities' capabilities to conduct translational clinical research as well as acquiring both homegrown and recruited talent. The solution—the Biomedical Science Initiative (BMS Initiative)—developed in 2000 with the goal of creating a sustainable biomedical sciences industry.

The trilogy of the government organizations responsible for creating the BMS– The Singapore Economic Development Board (EDB), which attracts investment into Singapore; EDB Investments (EDBI), the strategic corporate investment arm, and Agency for Science, Technology and Research, A*STAR, which promotes local research and talent– all insist that their commitment is unyielding and that the initiative is on track.

From 2011 to 2015, the government has committed SGD 16.1 billion (USD 13.2 billion) to R&D, of which about 40 percent has been allocated to biomedical sciences—a 12 percent increase from the previous budget allocation, explains Benjamin Seet, executive director of the Biomedical Research Council of A*STAR.

Benjamin Seet, Executive Director, Biomedical Research Council (A*Star)
This four-year span is considered the third phase of the initiative, which consists of working with the industry to generate improved economic outcomes.

The biomedical sciences manufacturing output has already increased four-fold from SGD 6 billion per year (USD 5 billion) in 2000 to SGD 27 billion (USD 22 billion) in 2011. Furthermore, 22 percent of the total manufacturing value-added is derived from biomedical sciences.

In order to keep the momentum, the EDB is continuing to pursue their "Host to Home" strategy, which aims for Singapore to become companies' home in Asia, rather than just being a host. After laying the groundwork for many "firsts", Bio*One, (the government's biomedical sciences investment division), is harnessing recent success in the medical technologies industry. Its past achievements include establishing S*BIO, Singapore's first private R&D company, and Maccine, the first preclinical company in Singapore.

James Kaw, Director Singapore Innovation Center (P&G)
Completing the trilogy is A*STAR. In addition to developing indigenous talent with a full "pipeline that extends as far into the future as 2022," A*STAR has enacted a Master Research Collaboration Agreement (MCRA) that has been signed by companies like Roche and GE Healthcare.

The dynamic of what Seet describes as MNCs moving "towards open innovation and leveraging on public sector research rather than developing everything in-house," will provide opportunities for collaboration. The MCRA will enable MNCs to work with different public institutions, including A*STAR institutes, universities, and hospitals, from one single entry point.

In addition, the Health Sciences Authority (HSA), Singapore's regulatory authority; the National University of Singapore (NUS), and the Nanyang Technological University (NTU), have played integral roles in fostering interconnectivity to further advance the BMS.

R&D expenditure in Singapore (1990-2010)
Although there have been setbacks in consolidating the Biopolis of Asia, like the 2010 closing of the Lilly Singapore Centre for Drug Discovery, Singapore is still attracting investments from big names. Novartis has committed USD 500 million to construct a biotech manufacturing facility. Proctor & Gamble's (P&G) 105,000 square foot, USD 192 million Innovation Center in the Biopolis is scheduled to be fully operational by mid-2013.

James Kaw, the director of the Singapore Innovation Center, cites the country's strength in the biomedical field as one of the principal reasons P&G decided on this location. The center, P&G's first in 20 years, will focus on beauty products, hair care, skin care, air care and personal health.

"What is important is that the industry continues to grow and the capabilities we have built are anchored in Singapore and can be redeployed," says Keat Chuan Yeoh, managing director of the EDB.

Augusto Muench, Regional Director South East Asia & MD Singapore Boehringer Ingelheim
Public-private partnerships (PPP) are part and parcel of the anchoring plan. GlaxoSmithKline (GSK), for example, has a SGD 2 million (USD 1.6 million) PPP between GSK Vaccines and A*STAR's Bioprocessing Technology Institute to collaborate on vaccine and adjuvant system-related research projects. In 2010, GSK launched the GSK-Singapore 10 Year Strategic Roadmap in partnership with the EDB. A joint fund of SGD 50 million (USD 41 million) is dedicated to building capabilities in the areas of green manufacturing and healthcare policy in Asia.


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here